Clinical trials: QTc Interval
Healthy
A Study of LY3039478 in Healthy Participants
The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods.
- Trial name
- NCT02659865
- Testing
- LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
CP-690,550 Thorough QTc Study
ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development.
- Trial name
- NCT01743677
- Testing
- CP-690,550, Moxifloxacin
- Where
- 2 sites in Belgium, Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects
This is a study designed to ascertain the effect of PF-04447943 on QT interval in healthy adult subjects. This is conducted as part of standard drug development.
- Trial name
- NCT02785770
- Testing
- PF-04447943, Moxifloxacin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females
- Trial name
- NCT00672984
- Testing
- immediate release guanfacine hydrochloride, moxifloxacin
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Shire
Congestive Heart Failure
Phase I Study of OPC-61815
To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on QT/QTc interval in healthy male subjects
- Trial name
- NCT03510663
- Testing
- OPC-61815 16mg, OPC-61815 32mg, Moxifloxacin
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Anxiety Disorders
Concentration-QT Study of Paroxetine in Healthy Adults
The primary purpose of the study is to evaluate the potential effect of paroxetine on QTc interval following escalating doses in healthy participants.
- Trial name
- NCT06065735
- Testing
- Paroxetine
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Thorough QT/QTc Study
Staccato Loxapine Thorough QT/QTc Study
The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.
- Trial name
- NCT00874237
- Testing
- Inhaled loxapine, Oral moxifloxacin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nova Pneuma Inc.
Prolonged QTc Interval
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and…
- Trial name
- NCT01860703
- Testing
- Deferiprone, moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Healthy
A TQT Study of Effect of M2951 on Cardiac Repolarization
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
- Trial name
- NCT07214935
- Testing
- Moxifloxacin, M2951 Low Dose, M2951 High Dose
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy Subjects
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
The study will assess the corrected QT (QTc) effects (electrocardiogram [ECG]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative…
- Trial name
- NCT05293171
- Testing
- 2 mg/kg BL-8040, 400 mg Moxifloxacin (1x400 mg tablet)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- BioLineRx, Ltd.
Healthy
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.
- Trial name
- NCT05630274
- Testing
- Selpercatinib, Moxifloxacin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
This 4-panel study will evaluate the safety, tolerability, pharmacokinetics (PK) and corrected QT interval (QTc) effect of MK-8189 versus placebo, as monotherapy in healthy participants (Panel A) including those of Japanese…
- Trial name
- MDCS (NCT03565068)
- Testing
- MK-8189, Background AAP Therapy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Long QT Syndrome
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects.
- Trial name
- NCT05906732
- Testing
- LQT-1213, Dofetilide 250 μg Cap
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
Healthy Volunteers
ADASUVE 2-dose Thorough QT/QTc Study
Assess the potential effects on the QT interval of 2 consecutive doses of ADASUVE administered 2 hours apart, in relation to placebo and an active control in healthy volunteers.
- Trial name
- NCT01854710
- Testing
- ADASUVE 10 mg 2 doses 2 hours apart, Oral moxifloxacin 400 mg
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
QT Intervals Changes, QTc Intervals Changes
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
The primary objective of this study is to assess the effect of a single therapeutic (50 mg) oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart rate (QTc), relative to placebo, in healthy…
- Trial name
- NCT04175808
- Testing
- Omecamtiv Mecarbil (OM), Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Healthy Study Participants
A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants
The purpose of the study is to evaluate the effects on cardiac repolarization of high-dose padsevonil (PSL) in comparison to placebo in healthy study participants.
- Trial name
- NCT04126343
- Testing
- Padsevonil, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Healthy
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and…
- Trial name
- NCT06215521
- Testing
- Pirtobrutinib, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dyslipidemias
A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval
This is a Phase 1, single centre, randomised, double blind (except for moxifloxacin), placebo and positive controlled, 4 way crossover study assessing the ECG effects of therapeutic and supratherapeutic doses of icosabutate in…
- Trial name
- NCT03577275
- Testing
- NST-4016 600mg, Moxifloxacin 400mg, NST-4016 2000mg
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Autoimmune Diseases
A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
- Trial name
- NCT04818229
- Testing
- CBP-307, Moxifloxacin (Avelox)
- Where
- 2 sites in United States, Australia
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Connect Biopharma Australia Pty Ltd